ライフサイエンスコーパス: epoetin

1 tment with recombinant human erythropoietin (epoetin).

2 herapy received filgrastim and 6.8% received epoetin.

3 igher in the comparison of peginesatide with epoetin.

4 matologic response before considering use of epoetin.

5 matologic response before considering use of epoetin.

6 ment with either subcutaneous or intravenous epoetin.

7 alysis treatment and intravenous maintenance epoetin.

8 gy (ASCO/ASH) recommendations for the use of epoetin.

9 ered, on average, an additional 3306 U/wk of epoetin.

10 versus 60,600 dollars and 64,311 dollars for epoetin.

11 ge for patients who continued treatment with epoetin (-0.75 g/L, -2.26 to 0.75) (p<0.0001 for both co

12 SP was threefold longer than for intravenous Epoetin (25.3 versus 8.5 h), a difference of 16.8 h (95%

13 ume of distribution was similar for NESP and Epoetin (52.4 +/- 2.0 ml/kg versus 48.7 +/-2.1 ml/kg; me

14 dialysis facility ownership and the dose of epoetin administered.

15 e, administered monthly, was as effective as epoetin, administered one to three times per week, in ma

16 Among 34 patients who received epoetin after the onset of PRCA, 56% regained epoetin re

17 design, the single-dose pharmacokinetics of Epoetin alfa (100 U/kg) and an equivalent peptide mass o

18 eekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120K arm) SC every 3 weeks for 18 addition

19 io, to either GM-CSF (0.3-5.0 microg/kg.d) + epoetin alfa (150 IU/kg 3 times/wk) or GM-CSF (0.3-5.0 m

20 Epoetin alfa (40,000 U) or placebo was administered week

21 sly (SC), followed by either standard weekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120

22 be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56

23 United States with darbepoetin alfa (DA) or epoetin alfa (EA).

24 ninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat

25 Epoetin alfa (EPO) robustly induced bone marrow erythrof

26 showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test), and Cox regression

27 Patients received epoetin alfa 10,000 U three times weekly, which could be

28 tarting chemotherapy, were randomized 2:1 to epoetin alfa 150 to 300 IU/kg (n = 251) or placebo (n =

29 Patients were treated with epoetin alfa 150 U/kg three times weekly, which could be

30 Patients received epoetin alfa 40,000 U once weekly, which could be increa

31 enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously (SC), followed by e

32 After three weekly doses of epoetin alfa 40,000 U, a dose of 120,000 U can be admini

33 ts who had received the Eprex formulation of epoetin alfa and 1 in a patient who had received Neoreco

34 erall tumor response was similar between the epoetin alfa and placebo groups after three chemotherapy

35 Epoetin alfa and placebo groups had similar median overa

36 Epoetin alfa and placebo patients (n = 109 and n = 115,

37 ; P=0.67) at 6 months did not differ between epoetin alfa and placebo, but declines in stroke volume

38 Percentages of patients in the epoetin alfa and the placebo groups requiring transfusio

39 s transfused during the 12-week study in the epoetin alfa and the placebo groups were 5.9 and 9.5, re

40 Concordantly, epoetin alfa appeared to increase hemoglobin levels and

41 Epoetin alfa appears to have a beneficial impact on pati

42 These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related

43 multiple times and pooling preservative-free epoetin alfa caused this outbreak of bloodstream infecti

44 This study assessed whether epoetin alfa could maintain RBV dose, improve quality of

45 The pharmacokinetics of epoetin alfa did not predict pharmacodynamic response in

46 t that in newly diagnosed patients with SCLC epoetin alfa does not affect tumor response to chemother

47 The use of epoetin alfa does not reduce the incidence of red-cell t

48 The results suggest that epoetin alfa effectively improves functional outcomes in

49 were punctured multiple times, and residual epoetin alfa from multiple vials was pooled and administ

50 the first week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV

51 ell units transfused (4.5+/-4.6 units in the epoetin alfa group and 4.3+/-4.8 units in the placebo gr

52 red in 4 of 45 (9%) patients in the GM-CSF + epoetin alfa group compared with 1 of 21 (5%) patients w

53 oncentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6+/-2.0

54 e interval {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3%

55 red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% conf

56 GM-CSF +/- epoetin alfa had no effect on mean platelet count.

57 ving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compar

58 Prescription of epoetin alfa has been associated with increased survival

59 ective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia

60 ted in patients who switched from placebo to epoetin alfa in the OLP.

61 inical trials have shown that treatment with epoetin alfa increases hemoglobin levels, reduces fatigu

62 Treatment with epoetin alfa is associated with an increase in the incid

63 Epoetin alfa is effective in improving the functional st

64 Epoetin alfa maintained RBV dose and improved QOL and Hb

65 s or reactions were associated with doses of epoetin alfa of more than 4000 U (multivariate odds rati

66 To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted i

67 olled clinical trial assessed the effects of epoetin alfa on transfusion requirements, hematopoietic

68 led trial (N93-004) evaluated the effects of epoetin alfa on tumor response to chemotherapy and survi

69 domly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered wit

70 In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in an

71 Fewer epoetin alfa patients than placebo patients required tra

72 s maintained in the prechemotherapy range in epoetin alfa patients, but decreased substantially in pl

73 ajority of these patients received Eprex, an epoetin alfa product marketed exclusively outside the Un

74 In conclusion, epoetin alfa provided clinically significant HRQL improv

75 One of six dosing epoetin alfa regimens for 15 days, as follows: 40,000 IU

76 inical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well a

77 Treatment with epoetin alfa resulted in significant increases in hemogl

78 Epoetin alfa safely and effectively ameliorates anemia a

79 Epoetin alfa significantly improved HgB and reduced tran

80 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-w

81 were randomly assigned to receive a dose of epoetin alfa targeted to achieve a hemoglobin level of 1

82 were associated with higher median doses of epoetin alfa than the 188 other sessions (6500 vs. 4000

83 ted from pooled epoetin alfa, empty vials of epoetin alfa that had been pooled, antibacterial soap, a

84 As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in eit

85 and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are sim

86 mmunity-based trial suggest that once-weekly epoetin alfa therapy increases hemoglobin levels, decrea

87 the 2,964 patients assessable for efficacy, epoetin alfa therapy resulted in significant increases i

88 Epoetin alfa therapy was also associated with a signific

89 Epoetin alfa therapy was associated with improved qualit

90 30, 1,047 patients completed all 4 months of epoetin alfa therapy.

91 The administration of the ESA epoetin alfa to critically ill trauma patients has been

92 Administration of epoetin alfa to older adult patients with heart failure

93 Addition of epoetin alfa to radical radiotherapy did not affect surv

94 he authors aimed to evaluate the efficacy of epoetin alfa treatment on the outcome of OHCA patients i

95 ized, double-blind clinical trial evaluating epoetin alfa versus placebo in anemic cancer patients.

96 igue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.

97 were maintained in 88% of patients receiving epoetin alfa vs. 60% of patients receiving placebo (P <

98 In addition, epoetin alfa was associated with a significant increase

99 As compared with placebo, epoetin alfa was associated with a significant increase

100 Epoetin alfa was associated with significant increases i

101 After the practice of pooling epoetin alfa was discontinued and the contaminated soap

102 Once-weekly epoetin alfa was well tolerated, with most adverse event

103 Epoetin alfa was well tolerated.

104 Epoetin alfa was well tolerated.

105 Epoetin alfa was well tolerated; the most common adverse

106 that preservative-free, single-use vials of epoetin alfa were punctured multiple times, and residual

107 Patients receiving epoetin alfa who had the greatest Hb increases from rand

108 or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarc

109 sized that treating anemia with subcutaneous epoetin alfa would be associated with reverse ventricula

110 Mean Hb increased by 2.2 +/- 1.3 g/dL (epoetin alfa) and by 0.1 +/- 1.0 g/dL (placebo) in the D

111 safety phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct E

112 mulating factor (GM-CSF) and erythropoietin (epoetin alfa) in anemic, neutropenic patients with myelo

113 Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia

114 erapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfu

115 ers of Eprex, Epogen (another formulation of epoetin alfa), and Neorecormon.

116 fusion and recombinant human erythropoietin (epoetin alfa).

117 eable with recombinant human erythropoietin (epoetin alfa).

118 a heavily glycosylated protein therapeutic (Epoetin Alfa).

119 t between groups (observation, 35.42 months; epoetin alfa, 31.47 months; hazard ratio, 1.04; 95% CI,

120 enter, placebo-controlled, clinical trial of epoetin alfa, 40,000 U subcutaneously, once weekly vs. m

121 anemic critically ill patients treated with epoetin alfa, all dosing regimens were well tolerated an

122 Epoetin alfa, compared with placebo, significantly decre

123 S. liquefaciens was isolated from pooled epoetin alfa, empty vials of epoetin alfa that had been

124 ety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke

125 which placebo patients were crossed over to epoetin alfa.

126 bel phase during which all patients received epoetin alfa.

127 23 to 28% of these patients were prescribed epoetin alfa.

128 ed hazards ratio of 1.309 (P =.052) favoring epoetin alfa.

129 948 to 3831 during treatment with GM-CSF +/- epoetin alfa.

130 o define the optimal doses and schedules for epoetin alfa.

131 Hb levels increased from baseline with epoetin alfa.

132 nt is somewhat greater with continued weekly epoetin alfa.

133 a mouse model, single-dose CNTO 530 (unlike epoetin-alfa or darbepoietin-alfa) bolstered red cell pr

134 erythroblasts at frequencies multifold above epoetin-alfa or darbepoietin-alfa.

135 quently can be treated via administration of epoetin-alfa, darbepoietin-alfa, or methoxy-PEG epoetin-

136 AKT activation were similar for CNTO 530 and epoetin-alfa.

137 the present study to determine if utilizing epoetin alpha (EPO) with or without a higher dose of RVN

138 ilities with fixed characteristics including epoetin alpha dosing.

139 a patient who was treated with fixed-dosage epoetin alpha in the poorest versus best performing unit

140 All three are epoetin alpha products, reputed to have similar glycosyl

141 owth factor injections (darbepoetin alpha or epoetin alpha) during combination therapy with standard

142 01 continues to support a positive effect of epoetin-alpha therapy on the quality of life of patients

143 Recombinant human erythropoietin (epoetin-alpha), an effective alternative to blood transf

144 ents and trials of longer-acting versions of epoetin-alpha, such as the novel erythropoiesis-stimulat

145 ogists and anemia managers adjusted doses of epoetin and intravenous iron as clinically indicated.

146 s individualized and specific application of epoetin and iron for each patient, and significant cost

147 anel found good evidence to recommend use of epoetin as a treatment option for patients with chemothe

148 anel found good evidence to recommend use of epoetin as a treatment option for patients with chemothe

149 hronic kidney disease patients who developed epoetin-associated PRCA and had 3 months or more follow-

150 Among chronic kidney disease patients with epoetin-associated PRCA, epoetin discontinuation and imm

151 We obtained reports of epoetin-associated pure red-cell aplasia from the Food a

152 en January 1998 and April 2004, 175 cases of epoetin-associated pure red-cell aplasia were reported f

153 isk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) trial.

154 d to intravenous methoxy polyethylene glycol-epoetin beta every 2 weeks (-0.71 g/L, 95% CI -2.20 to 0

155 igned to receive methoxy polyethylene glycol-epoetin beta every 2 weeks, and 224 to receive it every

156 ing intervals of methoxy polyethylene glycol-epoetin beta with standard epoetin treatment.

157 o had received Neorecormon (a formulation of epoetin beta); both are products that are marketed outsi

158 effectiveness of methoxy polyethylene glycol-epoetin beta, given intravenously at 2-week or 4-week in

159 l trial to lenalidomide or lenalidomide plus epoetin beta.

160 [SD, 9] vs. 18 weeks [SD, 7]; P = 0.004) of epoetin-beta than patients receiving monotherapy.

161 controlled trial investigated the effect of epoetin-beta to normalize hemoglobin values (13.0-15.0 g

162 etin-alfa, darbepoietin-alfa, or methoxy-PEG epoetin-beta.

163 In the absence of response, continuing epoetin beyond 6 to 8 weeks does not appear to be benefi

164 In the absence of response, continuing epoetin beyond 6-8 weeks does not appear to be beneficia

165 s likely to confer a clinical advantage over Epoetin by allowing less frequent dosing in patients tre

166 hemodialysis, subcutaneous administration of epoetin can maintain the hematocrit in a desired target

167 Iron overload before the availability of epoetin constituted a serious problem; our review of the

168 sease patients with epoetin-associated PRCA, epoetin discontinuation and immunosuppressive therapy or

169 erritin 500 to 1200 ng/ml, TSAT <or=25%, and epoetin dosage >or=225 IU/kg per wk or >or=22,500 IU/wk.

170 to investigate how ferric gluconate impacted epoetin dosage after DRIVE.

171 anemic dialysis patients receiving adequate epoetin dosages and have a ferritin 500 to 1200 ng/ml an

172 Weekly mean epoetin dose administered in December 2004 and the adjus

173 ession models were used to estimate the mean epoetin dose and dose adjustment by profit, chain, and a

174 27 +/- 18,021 IU/wk, P = 0.003), whereas the epoetin dose essentially did not change for patients in

175 The initial dose was based on the average epoetin dose given during the week before the switch.

176 There was no significant change in epoetin dose over 6 months in the ergocalciferol or plac

177 Epoetin dose requirements for the study group decreased

178 facilities, for-profit facilities increased epoetin doses 3-fold for patients with hematocrit levels

179 ialysis patients who were receiving adequate epoetin doses and who had ferritin levels between 500 an

180 conate maintains hemoglobin and allows lower epoetin doses in anemic hemodialysis patients with low T

181 d ownership are associated with variation in epoetin dosing in the United States.

182 ich a patient receives dialysis might affect epoetin dosing patterns and has implications for future

183 Different epoetin dosing patterns suggest that large for-profit ch

184 bcutaneous route, the average weekly dose of epoetin during the maintenance phase was 32 percent less

185 ess erythropoietin-stimulating agent (median epoetin-equivalent units per week: 5306 units/wk ferric

186 randomized controlled trial supports use of epoetin for patients with anemia associated with low-ris

187 Use of epoetin for patients with less severe anemia (hemoglobin

188 Use of epoetin for patients with less severe anemia (Hgb level

189 units of RBCs compared with 127 units in the epoetin group (P < .0001).

190 n in 1988, recombinant human erythropoietin (epoetin) has been standard treatment for patients with a

191 m EMERALD 2, peginesatide was noninferior to epoetin in maintaining hemoglobin levels (mean between-g

192 d clinical practice guideline for the use of epoetin in patients with cancer.

193 levels in renal anemia that is treated with epoetins is often incomplete and subject to much variati

194 ed that if recombinant human erythropoietin (epoetin) is administered subcutaneously rather than intr

195 iency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.

196 ts from the Food and Drug Administration and epoetin manufacturers were reviewed for information on c

197 esatide once monthly or continued to receive epoetin one to three times a week, with the doses adjust

198 ing patterns and has implications for future epoetin policies.

199 imilar patient case-mix, the average dose of epoetin ranged from 17,832 U/wk at chain 5 (nonprofit fa

200 nsistently administered the highest doses of epoetin regardless of anemia status.

201 ibution of iron deficiency toward anemia and epoetin resistance among end-stage renal disease (ESRD)

202 times more likely to receive filgrastim and epoetin, respectively, after controlling for other facto

203 The highest rates of epoetin responsiveness were observed among persons whose

204 the patients, immunosuppressive treatments, epoetin responsiveness, and hematologic recovery.

205 poetin after the onset of PRCA, 56% regained epoetin responsiveness.

206 ronic kidney disease developed antibodies to epoetin, resulting in pure red cell aplasia (PRCA).

207 Epoetin should be titrated once the hemoglobin concentra

208 t, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percen

209 gluconate group required significantly less epoetin than their DRIVE dose (mean change of -7527 +/-

210 target range, with an average weekly dose of epoetin that is lower than with intravenous administrati

211 Reinitiation of epoetin therapy among individuals could be considered if

212 Recombinant epoetin therapy and correction of the chronic anemia of

213 Epoetin therapy for dialysis-related anemia is the singl

214 overshooting target hemoglobin levels under epoetin therapy may be a source of concern.

215 ho were receiving long-term hemodialysis and epoetin therapy to treatment with either subcutaneous or

216 ialysis, despite concomitant erythropoietin (epoetin) therapy.

217 ical trials supports the use of subcutaneous epoetin thrice weekly (150 U/kg tiw) for a minimum of 4

218 ical trials supports the use of subcutaneous epoetin thrice weekly (150 U/kg) for a minimum of 4 week

219 were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 perce

220 Conventional treatment with epoetin to manage anaemia in chronic kidney disease need

221 re receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not r

222 = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).

223 ared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).

224 From 1998 to 2004, nearly 200 epoetin-treated persons with chronic kidney disease deve

225 incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), r

226 venously at 2-week or 4-week intervals, with epoetin treatment one to three times per week for haemog

227 stimulating agent is as safe as conventional epoetin treatment, and can maintain anaemia management i

228 lyethylene glycol-epoetin beta with standard epoetin treatment.

229 ts of supplementation with ergocalciferol on epoetin utilization and other secondary outcomes in pati

230 ficiency or deficiency, but had no effect on epoetin utilization or secondary biochemical and clinica

231 hropoietin antibodies were undetectable when epoetin was administered (89%).

232 At randomization, epoetin was increased 25% in both groups; further dosage

233 zed, controlled clinical trial comparing two epoetins were examined by the techniques of functional d

234 nalogue of recombinant human erythropoietin (Epoetin) which has an increased terminal half-life in an